CST 6.67% 8.0¢ castile resources ltd

japan ann, page-2

  1. 4,086 Posts.
    re: japan ann - content 14th April 2005
    ASX ANNOUNCEMENT
    Japanese Approval of QuantiFERON®-TB Gold
    Cellestis Limited is pleased to announce it has been advised by NichireiBiosciences Inc
    that our TB diagnostic product QuantiFERON®-TB Gold (termed QuantiFERON TB-2G in
    Japan) has been approved for sale in Japan by the Ministry of Health, Labor and Welfare.
    Approval by the Ministry of Health, Labor and Welfare was granted on 14th April 2005
    (Permit No:21700AMY00177000) and allows QuantiFERON-TB Gold to be sold in Japan as
    a diagnostic for tuberculosis infection. The first Japanese branded product has already
    been shipped to Japan and is available for sale.
    “It has taken time to go through the regulatory process, but we are pleased with the
    outcome as Japan represents a major market for QuantiFERON-TB Gold” said Dr Tony
    Radford, CEO of Cellestis. “QuantiFERON-TB Gold is of particular value in Japan as it
    cuts through the diagnostic problems caused by BCG vaccination to truly allow
    identification of those with TB infection. TB rates in Japan remain very high for a
    developed country, and widespread use of QuantiFERON-TB Gold will be of great benefit
    to their TB control.”
 
watchlist Created with Sketch. Add CST (ASX) to my watchlist
(20min delay)
Last
8.0¢
Change
0.005(6.67%)
Mkt cap ! $19.35M
Open High Low Value Volume
7.5¢ 8.1¢ 7.5¢ $22.67K 295.3K

Buyers (Bids)

No. Vol. Price($)
1 7000 7.6¢
 

Sellers (Offers)

Price($) Vol. No.
8.0¢ 103803 1
View Market Depth
Last trade - 14.08pm 16/07/2024 (20 minute delay) ?
CST (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.